Multiple Sclerosis — Neurophysiological Assessment in Patients With Multiple Sclerosis
Citation(s)
Boniface SJ, Mills KR, Schubert M Responses of single spinal motoneurons to magnetic brain stimulation in healthy subjects and patients with multiple sclerosis. Brain. 1991 Feb;114 ( Pt 1B):643-62.
Goodkin DE, Hertsgaard D, Seminary J Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. Arch Phys Med Rehabil. 1988 Oct;69(10):850-4.
Hallett M Transcranial magnetic stimulation: a primer. Neuron. 2007 Jul 19;55(2):187-99. Review.
Houdayer E, Comi G, Leocani L The Neurophysiologist Perspective into MS Plasticity. Front Neurol. 2015 Sep 3;6:193. doi: 10.3389/fneur.2015.00193. eCollection 2015. Review.
Murias M, Webb SJ, Greenson J, Dawson G Resting state cortical connectivity reflected in EEG coherence in individuals with autism. Biol Psychiatry. 2007 Aug 1;62(3):270-3. Epub 2007 Mar 6.
Nunez PL, Srinivasan R A theoretical basis for standing and traveling brain waves measured with human EEG with implications for an integrated consciousness. Clin Neurophysiol. 2006 Nov;117(11):2424-35. Epub 2006 Sep 22.
Nunez PL, Westdorp AF The surface Laplacian, high resolution EEG and controversies. Brain Topogr. 1994 Spring;6(3):221-6.
Pajevic S, Basser PJ, Fields RD Role of myelin plasticity in oscillations and synchrony of neuronal activity. Neuroscience. 2014 Sep 12;276:135-47. doi: 10.1016/j.neuroscience.2013.11.007. Epub 2013 Nov 28.
Srinivasan R Spatial structure of the human alpha rhythm: global correlation in adults and local correlation in children. Clin Neurophysiol. 1999 Aug;110(8):1351-62.
Thatcher RW, Krause PJ, Hrybyk M Cortico-cortical associations and EEG coherence: a two-compartmental model. Electroencephalogr Clin Neurophysiol. 1986 Aug;64(2):123-43.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.